PharmacoEconomics

, Volume 33, Issue 5, pp 535–536 | Cite as

Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration

  • Don Husereau
  • Michael Drummond
  • Stavros Petrou
  • Dan Greenberg
  • Josephine Mauskopf
  • Federico Augustovski
  • Andrew H. Briggs
  • David Moher
  • Elizabeth Loder
  • Chris Carswell
Letter to the Editor

Keywords

Economic Evaluation Discrete Choice Contingent Valuation Conjoint Analysis Discrete Choice Experiment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest

Don Husereau is Chair of the CHEERS Task Force, and has served on the Board of Directors for the study funder (ISPOR) as well as received directed contracts for unrelated work from ISPOR and support for travel to a face-to-face meeting to discuss the contents of the report. All authors have completed the ICMJE uniform disclosure from at www.icmje.org/coi.disclosure.pdf and declare: FA and MD have also served as board members for the study funder; FA, AHB, CC, MD, DG, DH, EL, JM, and SP were provided support for travel to a face-to-face meeting to discuss the contents of the report; FA and MD have received payment from the study sponsor for serving as co-editors for Value in Health; no other relationships or activities that could appear to have influenced the submitted work have occurred. CC is the editor of this journal.

References

  1. 1.
    Roberts T, Sanghera S, Frew E. Adapting the CHEERS statement for reporting cost-benefit analysis. Pharmacoeconomics (in press).Google Scholar
  2. 2.
    Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluations Publication Guidelines Task Force. Value Health. 2013;16(2) (in press).Google Scholar
  3. 3.
    Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Med. 2008;5(1):e20.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C, et al. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med. 2006;144(5):364–7.CrossRefPubMedGoogle Scholar
  5. 5.
    McIntosh E, Clarke P, Frew EJ, Louviere JJ. Applied Methods of Cost-benefit Analysis in Health Care. 1 edition. Oxford; New York: Oxford University Press; 2010.Google Scholar
  6. 6.
    Neumann PJ, Thorat T, Shi J, Saret CJ, Cohen JT. The changing face of the cost-utility literature, 1990–2012. Value Health J Int Soc Pharmacoecon Outcomes Res. 2015;18(2):271–7.CrossRefGoogle Scholar
  7. 7.
    Drummond MF, Sculpher MJ, Torrance G, O’Brien B, Stoddart G. Methods for the Economic Evaluation of Health Care Programmes. Third Edition. Oxford University Press; 2005.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Don Husereau
    • 1
  • Michael Drummond
    • 2
  • Stavros Petrou
    • 3
  • Dan Greenberg
    • 4
  • Josephine Mauskopf
    • 5
  • Federico Augustovski
    • 6
  • Andrew H. Briggs
    • 7
  • David Moher
    • 8
  • Elizabeth Loder
    • 9
  • Chris Carswell
    • 10
  1. 1.Institute of Health EconomicsEdmontonCanada
  2. 2.Centre for Health EconomicsUniversity of YorkYorkUK
  3. 3.Warwick Medical School, University of WarwickCoventryUK
  4. 4.Department of Health Systems Management, Faculty of Health SciencesBen-Gurion University of the NegevBeer-ShevaIsrael
  5. 5.RTI Health Solutions, Research Triangle ParkNCUSA
  6. 6.Health Economic Evaluation and Technology AssessmentInstitute for Clinical Effectiveness and Health Policy (IECS)Buenos AiresArgentina
  7. 7.Health Economics and Health Technology Assessment, Institute of Health and WellbeingUniversity of GlasgowGlasgowScotland
  8. 8.Clinical Epidemiology ProgramOttawa Hospital Research InstituteOttawaCanada
  9. 9.BMJLondonUK
  10. 10.PharmacoEconomicsAdis InternationalAucklandNew Zealand

Personalised recommendations